ETACEPT Injection (Etanercept)
Table of Content
Arthritis and disorders of the musculoskeletal system are among the most common chronic disorders that have a huge impact on quality of life and are the leading cause of disability worldwide. Currently available treatment options include NSAIDs and Steroids for symptomatic relief. DMARDs are Disease modifying Antirheumatic drugs that halt disease progression and prevent further joint damage in rheumatic disorders. However,approximately 40% of these patients are not controlled with DMARDs. In such cases,biologics like etanercept play a significant role in controlling the disease activity and make a positive difference in the lives of these patients.
Cipla launches ETACEPT the first biosimilar of etanercept in India.
ETACEPT contains etanercept,a recombinant human tumour necrosis factor receptor produced by recombinant DNA technology. ETACEPT binds to TNF-α,a cytokine that plays a very important role in the inflammation and joint damage in rheumatic disorders. It helps in modifying the course of the disease and prevents further damage to the joints.
ETACEPT is indicated in the treatment of:
ETACEPT can be used alone or in combination with methotrexate to treat active RA refractory to DMARDs,including methotrexate.
Severe,active RA in adults not previously treated with methotrexate.
Polyarticular-course Juvenile Idiopathic Arthritis (JIA)
Active polyarticular-course JIA refractory to methotrexate in children more than 2 years of age.
Psoriatic Arthritis (PsA)
Active and progressive PsA refractory to DMARDs.
Ankylosing Spondylitis (AS)
Severe,active AS refractory to conventional therapy.